Biofourmis buys remote cancer monitoring startup Gaido Health
The fast-moving, Boston-based healthcare analytics and digital therapeutics (DTx) startup
snapped up cancer monitoring firm Gaido Health from Takeda Pharmaceuticals in a move that will allow it to expand its portfolio of offerings and the condition areas it operates in,reports MedCity News.
US Health Systems Are Applying Precision Medicine：
Biofourmis primarily focused on monitoring and treating patients with heart conditions via wearables
its AI-powered platform,
providing physicians a fuller picture into patients’ heart health and paving the way for more accurate, personalized care.
a recent Center for Connected Medicine survey：
But its move into oncology is a smart one, considering $151 billion is spent annually on cancer care in the US —
oncology tops the list of use cases for precision medicine among US health systems with initiatives underway, per a recent Center for Connected Medicine survey.
The Gaido Health purchase：
is the latest in a spate of activity signaling that Biofourmis is casting a wide net across the healthcare ecosystem —
which should benefit the startup both during the coronavirus pandemic and beyond.
Business Insider